Towards investigation, development and introduction of cefiderocol in children: product brief

· World Health Organization
eBook
8
페이지
적용 가능
검증되지 않은 평점과 리뷰입니다.  자세히 알아보기

eBook 정보

In November-December 2022, WHO undertook a Paediatric Drug Optimization (PADO) exercise for antibiotics, to: identify antibiotics with an approved indication for children for which age-appropriate formulations are missing that need to be given priority for development (PADO priority list); and pipeline or approved antibiotics without an indication for children to be given priority for further investigation and development for children (PADO watch list). Cefiderocol was included in the PADO priority list considering its efficacy against multiple pathogens in the WHO Bacterial Priority Pathogens List, its favorable resistance and cross-resistance profile and considering that clinical trials involving children are ongoing.

This information note aims to provide a summary of cefiderocol’s characteristics (regulatory approvals, current formulations, inclusion in the WHO EML etc), current and planned paediatric studies (including neonates) and initiatives to ensure prompt access for all people in need, as well as lay out interventions that should be prioritized by researchers and funders for cefiderocol development, as well as, more broadly for antibiotics that are much needed in children.

이 eBook 평가

의견을 알려주세요.

읽기 정보

스마트폰 및 태블릿
AndroidiPad/iPhoneGoogle Play 북 앱을 설치하세요. 계정과 자동으로 동기화되어 어디서나 온라인 또는 오프라인으로 책을 읽을 수 있습니다.
노트북 및 컴퓨터
컴퓨터의 웹브라우저를 사용하여 Google Play에서 구매한 오디오북을 들을 수 있습니다.
eReader 및 기타 기기
Kobo eReader 등의 eBook 리더기에서 읽으려면 파일을 다운로드하여 기기로 전송해야 합니다. 지원되는 eBook 리더기로 파일을 전송하려면 고객센터에서 자세한 안내를 따르세요.